angiotensin converting enzyme 2

Subscribe to Selected New Research on angiotensin converting enzyme 2

103 relevant articles (3 outcomes, 13 trials/studies) found for this Bio-Agent

Description: a homologue of angiotensin-converting enzyme (ACE), hydrolyzes carboxy-terminal leucine from angiotensin I to form angiotensin 1-9; 42% identical to angiotensin-converting enzyme in its catalytic domain; a target of SARS Virus

Also Known As:

ACE-related carboxypeptidase; ACE2 enzyme; ACE2 protein, human; ACEH protein, human; Ace2 protein, mouse; Ace2 protein, rat; Angiotensin-converting enzyme-related carboxypeptidase; angiotensin I converting enzyme (peptidyl-dipeptidase A) 2, human; angiotensin I converting enzyme (peptidyl-dipeptidase A) 2, mouse; angiotensin I converting enzyme (peptidyl-dipeptidase A) 2, rat; angiotensin converting enzyme 2, human

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Enzymes: 25587

Hydrolases: 580

Peptide Hydrolases: 5762

Exopeptidases: 34

Peptidyl-Dipeptidase A: 8830

angiotensin converting enzyme 2: 103

Biological Factors: 931

Antigens: 95584

Surface Antigens: 3817

Differentiation Antigens: 874

CD Antigens: 32

Peptidyl-Dipeptidase A: 8830

angiotensin converting enzyme 2: 103

Biological Markers: 21607

Differentiation Antigens: 874

CD Antigens: 32

Peptidyl-Dipeptidase A: 8830

angiotensin converting enzyme 2: 103

Experts

1.	Kuba, Keiji: 3 articles (05/2008 - 06/2006)
2.	Wysocki, Jan: 3 articles (05/2008 - 11/2006)
3.	Imai, Yumiko: 3 articles (05/2008 - 06/2006)
4.	Penninger, Josef M: 3 articles (05/2008 - 06/2006)
5.	Batlle, Daniel: 3 articles (05/2008 - 11/2006)
6.	Raizada, Mohan K: 2 articles (03/2008 - 05/2005)
7.	Grobe, Justin L: 2 articles (03/2008 - 05/2005)
8.	Katovich, Michael J: 2 articles (03/2008 - 05/2005)
9.	Burrell, Louise M: 2 articles (09/2007 - 03/2003)
10.	Moore, Michael J: 2 articles (10/2004 - 10/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/01/2006 - "Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese." 07/01/2004 - "Recent intriguing findings from genetic linkage, knockout, and physiologic studies in mice and rats led us to conduct the first investigation of the novel angiotensin-converting enzyme 2 gene (ACE2) in human hypertension (HT). " 05/01/2008 - "Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats." 03/01/2008 - "Angiotensin converting enzyme 2 (ACE2) has been linked to cardiac dysfunction and hypertension-induced cardiac pathophysiology. " 12/01/2007 - "Experimental evidence indicates that angiotensin-converting enzyme 2 (ACE2), a homologue of human ACE, might negatively regulate the activated renin-angiotensin-aldosterone system (RAAS) and might function as a protective regulator in the pathogenesis of hypertension. " Order ALL the reference details at left...
2.	Cardiovascular Diseases (Cardiovascular Disease) 12/01/2004 - "Angiotensin-converting enzyme 2 (ACE2) is considered an important therapeutic target for controlling cardiovascular diseases and severe acute respiratory syndrome (SARS) outbreaks. " 05/01/2008 - "Angiotensin-converting enzyme 2 (ACE2) is a key renin-angiotensin system enzyme involved in balancing the adverse effects of angiotensin II on the cardiovascular system, and its overexpression by gene transfer is beneficial in cardiovascular disease. " 05/01/2006 - "This will be accomplished by discussion of the following: (i) summary of our current understanding of the RAS with a focus on the systemic versus tissue counterparts as they relate to hypertension and other cardiovascular pathologies; (ii) the newly discovered ACE2 enzyme with its physiological and pathophysiological implications; (iii) summary of the current antihypertensive pharmacotherapy and its limitations; (iv) the discovery and design of ACE inhibitors; (v) the emerging concepts for ACE2 drug design; (vi) the current status of genetic targeting of the RAS; (vii) the potential of ACE2 as a therapeutic target for hypertension and cardiovascular disease treatment; and (viii) future perspectives for the treatment of cardiovascular diseases." 02/01/2008 - "BACKGROUND: The discovery of angiotensin-converting enzyme 2 (ACE2) has shed light on the potential therapy for cardiovascular disease, owing to its key role in the formation of vasoprotective peptide angiotensin (Ang 1-7) from angiotensin (Ang) II. The aim of this study was to evaluate whether ACE2 overexpression could protect human monocyte cell line (THP-1) macrophages from angiotensin II-induced monocyte chemoattractant protein-1 (MCP-1) formation. " 09/01/2005 - "Angiotensin converting enzyme 2 (ACE2), a newly discovered member of the renin-angiotensin system (RAS), is a potential therapeutic target for the control of cardiovascular disease owing to its key role in the formation of vasoprotective peptides from angiotensin II. The aim of the present study was to evaluate whether overexpression of ACE2 could protect the heart from angiotensin II-induced hypertrophy and fibrosis. " Order ALL the reference details at left...
3.	Acute Lung Injury 05/01/2008 - "The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice." 08/01/2009 - "The abundant presence of angiotensin-converting enzyme 2 (ACE2) in the lungs and its impressive effect in the prevention of acute lung injury led us to test the hypothesis that pulmonary overexpression of this enzyme could produce beneficial outcomes against pulmonary hypertension. " 12/01/2008 - "Angiotensin-converting enzyme (ACE) and its homologue angiotensin-converting enzyme 2 (ACE2) are critical counter-regulatory enzymes of the renin-angiotensin system, and have been implicated in cardiac function, renal disease, diabetes, atherosclerosis and acute lung injury. " Order ALL the reference details at left...
4.	Pulmonary Hypertension (Ayerza Syndrome) 08/01/2009 - "Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer." 06/01/2009 - "Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension." 08/01/2009 - "The abundant presence of angiotensin-converting enzyme 2 (ACE2) in the lungs and its impressive effect in the prevention of acute lung injury led us to test the hypothesis that pulmonary overexpression of this enzyme could produce beneficial outcomes against pulmonary hypertension. " Order ALL the reference details at left...
5.	Hypertrophy 02/01/2007 - "Our previous studies have demonstrated that overexpression of angiotensin-converting enzyme 2 (ACE2) prevents cardiac remodeling and hypertrophy during chronic infusion of angiotensin II (ANG II). " 09/01/2005 - "Angiotensin converting enzyme 2 (ACE2), a newly discovered member of the renin-angiotensin system (RAS), is a potential therapeutic target for the control of cardiovascular disease owing to its key role in the formation of vasoprotective peptides from angiotensin II. The aim of the present study was to evaluate whether overexpression of ACE2 could protect the heart from angiotensin II-induced hypertrophy and fibrosis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Angiotensin II
2.	angiotensin I (1-7)
3.	Type 1 Angiotensin Receptor
4.	Antigens
5.	Angiotensins
6.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
7.	Peptides
8.	HLA-B*4601
9.	telmisartan (Micardis)
10.	puerarin

Related Therapies and Procedures

1.	Surgical Instruments (Clip)
2.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Hypertension

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3948 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>